| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cereblon
Ligands for E3 Ligase (specific E3 ligase target not specified in literature). |
|---|---|
| ln Vitro |
As an E3 ligase ligand fragment, KB02-COOH itself has no intrinsic degradation activity; its function is to recruit an E3 ubiquitin ligase complex when incorporated into a complete PROTAC molecule. It is a synthetic intermediate rather than a biologically active compound in its own right.
|
| ln Vivo |
No specific in vivo activity has been reported for this fragment alone; its in vivo degradation effects are observed only when conjugated to a target protein ligand to form a complete PROTAC molecule such as KB02-JQ1 or KB02-SLF.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is confirmed by analytical methods such as HPLC and NMR, with a standard purity of 98.34%. The structure is verified by mass spectrometry.
|
| Cell Assay |
N/A; this fragment is not tested alone in cell-based assays. In a typical procedure, it is conjugated to a target protein ligand (e.g., JQ1 or SLF) via amide bond formation using standard coupling reagents. The resulting PROTAC is then tested for target degradation in cells.
|
| Animal Protocol |
N/A; no animal studies are performed with the fragment alone. For in vivo studies of the final PROTAC conjugate, the molecule is formulated in a suitable vehicle (e.g., 10% DMSO, 40% PEG300, 5% Tween-80, 45% saline) and administered to animal models.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 283.71, a molecular formula of C13H14ClNO4, and is typically stored as a powder at -20degC for up to 3 years or in a solvent at -80degC for 2 years. It is soluble in DMSO (66.67 mg/mL). For in vivo formulation, it can be dissolved in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human therapeutic or clinical applications. Standard chemical safety precautions should be followed during handling. The product has not been fully validated for medical applications.
|
| References | |
| Additional Infomation |
Ligand-dependent protein degradation has become a highly attractive strategy for pharmacologically modulating cellular protein content. However, to date, only a handful of E3 ubiquitin ligases have been found to participate in this process. This study employs a chemical proteomics strategy, utilizing broadly reactive, cysteine-directed electrophilic fragments coupled with selective ligands targeting intracellular proteins (e.g., SLF for FKBP12, JQ1 for BRD4), to screen for heterobifunctional degradative compounds (or proteolytic-targeting chimeras, PROTACs) that function by covalently binding to E3 ubiquitin ligases. This method identified DCAF16—a substrate recognition component of the previously little-studied CUL4-DDB1 E3 ubiquitin ligase—as a target for electrophilic PROTACs that promote the degradation of nuclear proteins. We found that modification of only a small fraction (~10–40%) of DCAF16 supports protein degradation, suggesting that electrophilic PROTACs have the potential to induce novel substrate degradation without significantly interfering with the function of the involved E3 ligases.
KB02-COOH is a key building block for the synthesis of KB02-based PROTACs. The KB02 ligand is known to recruit a specific E3 ubiquitin ligase (target not specified), and this fragment enables the controlled conjugation of that ligase to target protein ligands for targeted protein degradation research. |
| Molecular Formula |
C13H14CLNO4
|
|---|---|
| Molecular Weight |
283.707562923431
|
| Exact Mass |
283.061
|
| CAS # |
2375196-30-6
|
| Related CAS # |
KB02-SLF;2384184-40-9;KB02-JQ1;2384184-44-3
|
| PubChem CID |
137347746
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
350
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC2=C(C=CC(=C2)OCC(=O)O)N(C1)C(=O)CCl
|
| InChi Key |
ZWIYQLVGARZWJJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H14ClNO4/c14-7-12(16)15-5-1-2-9-6-10(3-4-11(9)15)19-8-13(17)18/h3-4,6H,1-2,5,7-8H2,(H,17,18)
|
| Chemical Name |
2-[[1-(2-chloroacetyl)-3,4-dihydro-2H-quinolin-6-yl]oxy]acetic acid
|
| Synonyms |
KB02-COOH; 2375196-30-6; SCHEMBL22075942; Acetic acid, 2-[[1-(2-chloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl]oxy]-; 2-{[1-(2-chloroacetyl)-1,2,3,4-tetrahydroquinolin-6-yl]oxy}acetic acid; 2-((1-(2-chloroacetyl)-1,2,3,4-tetrahydroquinolin-6-yl)oxy)acetic acid; KB02-COOH?; 2-[[1-(2-chloroacetyl)-3,4-dihydro-2H-quinolin-6-yl]oxy]acetic acid;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~66.67 mg/mL (~234.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (17.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (17.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (17.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5247 mL | 17.6236 mL | 35.2473 mL | |
| 5 mM | 0.7049 mL | 3.5247 mL | 7.0495 mL | |
| 10 mM | 0.3525 mL | 1.7624 mL | 3.5247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
